👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Bruker director Richard Packer sells $193,682 in stock

Published 12/03/2024, 04:51 PM
BRKR
-

Richard A. Packer, a director at Bruker Corp (NASDAQ:BRKR), recently sold 3,350 shares of the company's common stock. The shares were sold at an average price of $57.8157, resulting in a total transaction value of $193,682. The transaction occurred as Bruker, an $8.7 billion scientific instruments manufacturer, trades near its current InvestingPro Fair Value estimate with a "GOOD" financial health rating.

In the same transaction, Packer exercised stock options to acquire 10,000 shares at a price of $19.12 per share. Following these transactions, Packer holds 80,904 shares of Bruker Corp. While analysts maintain a bullish outlook with price targets reaching up to $85, InvestingPro analysis reveals 10 additional key insights about Bruker's valuation and growth prospects, available exclusively to subscribers.

In other recent news, Bruker Corporation has made significant strides in its operations. The company's third-quarter earnings of 2024 showed a year-over-year revenue increase of 16.4%, amounting to $864.4 million, attributed to organic growth and recent acquisitions. However, the company has revised its full-year 2024 guidance downwards due to slower recoveries in the biopharma sector and Chinese market demand. The non-GAAP diluted EPS for Q3 was reported at $0.60, marking a decrease from the previous year's $0.74.

Additionally, the company unveiled the Dimension Nexus atomic force microscope (AFM), a notable addition to its Dimension AFM product line. This new system features the latest-generation NanoScope 6 controller and offers over 50 AFM modes, including Bruker’s exclusive PeakForce Tapping technology. The Dimension Nexus is expected to benefit a wide range of research applications due to its compact, upgradable design and large-sample analysis capacity.

These are recent developments for Bruker, which anticipates a muted recovery in 2025 and normalized market growth rates by 2026. Despite facing challenges in the biopharma sector and Chinese market, the company remains committed to its growth strategy and operational improvements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.